There is huge upward potential in health care stocks of billionaire Ken Fisher

We recently released a list 10 healthcare stocks from billionaire Ken Fisher with huge upward potential. In this article, we will explore the huge upward potential of health care stock sales between Merck (NYSE:MRK) and other billionaire Ken Fisher.

The healthcare industry is an important part of global well-being and economic resilience and is undergoing significant changes. The industry, believed to account for more than 10% of global GDP, will enter a new era characterized by demographic shifts, digital innovation and regulatory restructuring. As of 2025, stakeholders in the life sciences, diagnostics and healthcare services ecosystem face a conundrum: Despite abundant growth opportunities, stability is threatened by ongoing financial pressures, growing operational complexity and geopolitical risks.

Healthcare income in the United States remains under pressure. EBITDA's share of national health spending has dropped by 150 basis points since 2019, which has a significant impact on both payers and providers. McKinsey. this World Health Organization It is predicted that by 2030, there will be a reported shortage of 10 million medical staff, limited reimbursement growth and high inflation prices worldwide. At the same time, digital transformation has become important. according to Deloitte90% of executives in global health systems are expected to adopt digital technologies faster, with more than 70% of them intending to improve operational efficiency in 2025.

Artificial intelligence (AI) is at the heart of this change. AI, once aspiring, is now a destructive force that can improve everything from medical diagnosis to hospital logistics. EU institutions see artificial intelligence as a crucial thing for modernizing public health. this European Health Data Space (EHDS) will be launched in 2025, and the European Commission’s AI Act 2024 is designed to ensure AI technology is reliable and secure while promoting access to high-quality, interoperable health data. These frameworks, together with the revised Product Liability Directive, provide legal protection to patients and developers by simplifying the liability standards for defective AI systems.

However, there are still problems. Incorporating AI into clinical operations requires consistent funding, cultural acceptance and regulatory clarity. Data, ethical considerations and biases on the complexity of proxy AI solutions (tools that autonomously execute multi-step healthcare processes). Despite these challenges, practical applications are still attractive: AI is currently used for early identification of sepsis, breast cancer screening, and drug development, with the potential to shorten drug development timelines and improve patient outcomes.

Meanwhile, recent geopolitical developments are shading the global healthcare supply network. In April 2025, President Donald Trump announced a large number of tariffs, including a 10% benchmark and a target tax on medical devices, which could undermine the opportunity to obtain important inputs such as diagnostic tools and protective equipment. "Trump unveiled on Wednesday was stupid, wrong, extreme and ignorant trade," said billionaire investor Ken Fisher in a stern prosecution of the proposal. In addition, Morningstar and Fitch Analysts warn that hospitals are rising costs, which are already dealing with low profit margins and limiting pricing options.

These changes (technology, legislation and geopolitics) occur in a cautious optimism context. The healthcare industry remains strong despite forecasts for U.S. GDP growth to fall from 2.7% in 2024 to 1.5% in 2025. With AI integration deepening, policy clarity, and resetting investment cycles, the industry may be ready for a new era of growth.

To create 10 health care stocks from our billionaire Ken Fisher with huge upside potential, we looked at Ken Fisher’s Q4 2024 Q2024 13F SEC filing to find health care stocks in his portfolio. Then, based on the time of writing, we selected 10 stocks with the highest upside potential based on average analyst price forecasts. Then sort the stocks by their predicted upward space. The strategy highlights the most promising healthcare investments in Fisher’s existing portfolio. In addition, these stocks also provide hedge fund sentiment for these stocks, just like the Internal Monkey’s Fourth Quarter 2024 database.

Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).

Merck: There is huge upward potential in health care stocks of billionaire Ken Fisher

Close-up of a man's hand holding a bottle of medicine.

Upward potential: 48.91%

Number of hedge fund holders: 91

Oncology, Vaccines and Infectious Diseases in Merck (NYSE:MRK) is a leading global healthcare company engaged in oncology diseases in both human and animal health. The company is known for its innovation-driven pipeline and it has been making substantial R&D investments while negotiating the dynamics of global markets.

Merck (NYSE:MRK) had a total sales volume of $15.6 billion, 7% higher than the previous year (9% EX-FX). Keytruda's sales grew 21% to $7.8 billion due to global demand for metastatic and early-stage malignancy. Additionally, the company's animal health division reported a 13% growth rate. However, due to the high inventory levels of distribution partner Zhifei, Gardasil's sales fell by 18% due to shipping to China. However, Merck remains optimistic about Gardasil's long-term global outlook.

The company's core business development is expected to offset the challenges facing Gardasil in China, with revenue forecasts ranging from $64.1 to $65.6 billion in 2025, with non-GAAP EPS of $8.88 to $9.03. In addition to increasing dividends, Merck (NYSE:MRK) has also increased its authorization for share buybacks to $12 billion, enhancing shareholder returns. It is worth noting that the pipeline contains more than 20 potential blockbusters, such as Winrevair for pulmonary hypertension, which has been approved in more than 35 countries with initial sales of $200 million.

Following a promising third phase discovery in patients with TGCT, Merck (NYSE:MRK) exercised its global commercialization rights to Pimicotinib, a CSF-1R inhibitor created by Abbisko Therapeutics, which expanded its oncology on March 31, 2025. The $85 million acquisition expands its broad oncology base and Merck's long-term growth prospects have improved.

Therefore, Merck (NYSE:MRK) continues to be a high-criminal pharmaceutical investment in Ken Fisher's equity portfolio due to its innovative approach, diversified portfolio and dedication to capital discipline.

Overall, MRK Ranked second There is huge upward potential in the healthcare stock of our billionaire Ken Fisher. Although we acknowledge the potential of these companies, our belief lies in the belief that certain AI stocks have greater hope and can provide higher returns in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for AI stocks that are more promising than MRK but have less than 5 times its earnings, check out our report Cheapest AI stocks.

Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.

Disclosure: None. This article was originally published in Inside monkey.